Matrix metalloproteinase: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
Line 70: | Line 70: | ||
**[[1qia]], [[1qic]], [[1cqr]], [[1slm]] - hMMP catalytic domain<BR /> | **[[1qia]], [[1qic]], [[1cqr]], [[1slm]] - hMMP catalytic domain<BR /> | ||
**[[3ohl]], [[3oho]], [[1g49]], [[1ciz]], [[1b8y]], [[1caq]], [[1usn]], [[2usn]], [[1ums]], [[1umt]], [[2d1n]], [[2d1o]], [[2ow9]], [[1bqo]], [[1g4k]], [[1b3d]], [[1biw]], [[1c3i]], [[1d5j]], [[1d7x]], [[1d8f]], [[1d8m]], [[1g05]], [[1hfs]], [[1hy7]], [[2srt]], [[4dpe]], [[4g9l]], [[4ja1]] - hMMP catalytic domain + inhibitor<br /> | **[[3ohl]], [[3oho]], [[1g49]], [[1ciz]], [[1b8y]], [[1caq]], [[1usn]], [[2usn]], [[1ums]], [[1umt]], [[2d1n]], [[2d1o]], [[2ow9]], [[1bqo]], [[1g4k]], [[1b3d]], [[1biw]], [[1c3i]], [[1d5j]], [[1d7x]], [[1d8f]], [[1d8m]], [[1g05]], [[1hfs]], [[1hy7]], [[2srt]], [[4dpe]], [[4g9l]], [[4ja1]], [[5uwn]], [[5uwm]], [[5uwk]], [[5uwl]] - hMMP catalytic domain + inhibitor<br /> | ||
**[[1c8t]] - hMMP catalytic domain (mutant) + inhibitor<br /> | **[[1c8t]] - hMMP catalytic domain (mutant) + inhibitor<br /> | ||
**[[1uea]] - hMMP catalytic domain + TIMP-1<BR /> | **[[1uea]] - hMMP catalytic domain + TIMP-1<BR /> | ||
Line 81: | Line 81: | ||
**[[2mze]] – hpro-MMP (mutant) - NMR<br /> | **[[2mze]] – hpro-MMP (mutant) - NMR<br /> | ||
**[[2mzh]], [[2mzi]] – hpro-MMP (mutant) + membrane bilayer - NMR<br /> | **[[2mzh]], [[2mzi]] – hpro-MMP (mutant) + membrane bilayer - NMR<br /> | ||
**[[5ue5]], [[5ue2]] – hMMP (mutant) + heparin - NMR<br /> | |||
*MMP8 neutrophil collagenase | *MMP8 neutrophil collagenase | ||
Line 93: | Line 94: | ||
**[[1l6j]] - pro-hMMP<BR /> | **[[1l6j]] - pro-hMMP<BR /> | ||
**[[1itv]] – hMMP haemopexin-like domain<br /> | **[[1itv]] – hMMP haemopexin-like domain<br /> | ||
**[[1gkc]], [[4xct]], [[4wzv]], [[5cuh]], [[5i12]] - hMMP catalytic domain + inhibitor<br /> | **[[1gkc]], [[4xct]], [[4wzv]], [[5cuh]], [[5i12]], [[5ue4]], [[5ue3]], [[5th6]] - hMMP catalytic domain + inhibitor<br /> | ||
**[[2ovx]], [[2ovz]], [[2ow0]], [[2ow1]], [[2ow2]], [[1gkd]], [[4h1q]], [[4h82]], [[4hma]], [[4h2e]], [[4h3x]] - hMMP catalytic domain (mutant) + inhibitor<br /> | **[[2ovx]], [[2ovz]], [[2ow0]], [[2ow1]], [[2ow2]], [[1gkd]], [[4h1q]], [[4h82]], [[4hma]], [[4h2e]], [[4h3x]], [[6esm]] - hMMP catalytic domain (mutant) + inhibitor<br /> | ||
**[[4jij]], [[4jqg]] - hMMP catalytic domain (mutant) + FRET substrate<br /> | **[[4jij]], [[4jqg]] - hMMP catalytic domain (mutant) + FRET substrate<br /> | ||
**[[5th9]] - hMMP catalytic domain + antibody<br /> | |||
*MMP10 stromelysin 2 | *MMP10 stromelysin 2 | ||
Line 115: | Line 117: | ||
**[[2jxy]] - hMMP hemopexin-like domain - NMR<BR /> | **[[2jxy]] - hMMP hemopexin-like domain - NMR<BR /> | ||
**[[3n2u]], [[3n2v]], [[2wo8]], [[2wo9]], [[2woa]], [[1utt]], [[1utz]], [[1ros]], [[3rts]], [[3rtt]] – hMMP catalytic domain + inhibitor<br /> | **[[3n2u]], [[3n2v]], [[2wo8]], [[2wo9]], [[2woa]], [[1utt]], [[1utz]], [[1ros]], [[3rts]], [[3rtt]] – hMMP catalytic domain + inhibitor<br /> | ||
**[[3lk8]], [[3lik]], [[3lil]], [[3lir]], [[3ljg]], [[3nx7]], [[3lka]], [[3ehx]], [[3ehy]], [[3f15]], [[3f16]], [[3f17]], [[3f18]], [[3f19]], [[3f1a]], [[1y93]], [[1rmz]], [[1os2]], [[1os9]], [[2hu6]], [[3ts4]], [[3tsk]], [[3uvc]], [[4gql]], [[4gr0]], [[4gr3]], [[4gr8]], [[4h30]], [[4h49]], [[4h76]], [[4h84]], [[4io3]], [[1jk3]],[[4efs]], [[4gql]], [[4gr0]], [[4gr3]], [[4gr8]], [[4guy]], [[4h30]], [[4h49]], [[4h76]], [[4h84]], [[4i03]], [[5cxa]], [[5czm]], [[5d2b]], [[5d3c]], [[5i0l]], [[5i2z]], [[5i3m]], [[5i43]], [[5i4o]], [[5l79]], [[5l7f]], [[5lab]] - hMMP catalytic domain (mutant) + inhibitor<br /> | **[[3lk8]], [[3lik]], [[3lil]], [[3lir]], [[3ljg]], [[3nx7]], [[3lka]], [[3ehx]], [[3ehy]], [[3f15]], [[3f16]], [[3f17]], [[3f18]], [[3f19]], [[3f1a]], [[1y93]], [[1rmz]], [[1os2]], [[1os9]], [[2hu6]], [[3ts4]], [[3tsk]], [[3uvc]], [[4gql]], [[4gr0]], [[4gr3]], [[4gr8]], [[4h30]], [[4h49]], [[4h76]], [[4h84]], [[4io3]], [[1jk3]],[[4efs]], [[4gql]], [[4gr0]], [[4gr3]], [[4gr8]], [[4guy]], [[4h30]], [[4h49]], [[4h76]], [[4h84]], [[4i03]], [[5cxa]], [[5czm]], [[5d2b]], [[5d3c]], [[5i0l]], [[5i2z]], [[5i3m]], [[5i43]], [[5i4o]], [[5l79]], [[5l7f]], [[5lab]], [[6ekn]], [[6ela]], [[6enm]], [[6eox]], [[5n5k]], [[5n5j]] - hMMP catalytic domain (mutant) + inhibitor<br /> | ||
**[[2oxn]], [[2oxz]], [[2oxw]] - hMMP catalytic domain (mutant) + peptide<br /> | **[[2oxn]], [[2oxz]], [[2oxw]] - hMMP catalytic domain (mutant) + peptide<br /> | ||
**[[2n8r]] - hMMP catalytic domain (mutant) + collagen peptide – NMR<br /> | **[[2n8r]] - hMMP catalytic domain (mutant) + collagen peptide – NMR<br /> | ||
Line 136: | Line 138: | ||
**[[3c7x]] – hMMP hemopexin-like domain<br /> | **[[3c7x]] – hMMP hemopexin-like domain<br /> | ||
**[[2mqs]] - hMMP + collagen<br /> | **[[2mqs]] - hMMP + collagen<br /> | ||
**[[5h0u]] - hMMP + polyHis<br /> | |||
*MMP16 Membrane T3 | *MMP16 Membrane T3 |
Revision as of 11:41, 5 August 2018
FunctionMatrix metalloproteinases (MMP) are Zinc-dependent endopeptidases. MMP degrades extracellular matrix proteins. They are inhibited by proteases called tissue inhibitors of metalloproteinase (TIMP). The pro-MMP contains a pro-peptide which must be removed to render the MMP active[1]. See details in MMPs are produced by 28 different genes and are classified according to their protein substrates.
RelevanceMMPs have a role in cancer progression[2]. MMP-2 and MMP-9 secretion is elevated in ovarian cancer and are associated with poor prognosis[3]. MMP-8, MMP-9, MMP-13 and MMP-14 have a role in periodontal diseases[4]. MT1-MMP-TIMP-1 complexThe human matrix metalloproteinases (MMPs) family comprises a large group of structurally homologous zinc-dependent endopeptidases (e.g. (darkmagenta) and (magenta), ) that perform a wide variety of biological roles. In general, the MMPs are inhibited unselectively by all four known tissue inhibitors of metalloproteinases (TIMPs 1-4) which have 40-50% sequence identity. For example, can form complex with (1uea, colored orange). (cyan) is mainly composed of the N-terminal segment that approaches the active site, the AB loop (Thr33-Tyr35), the CD loop (Ala65-Cys70), and the EF loop (Thr97-Ser100). The pivotal residue, threonine 98 (Thr98), is shown as red sticks. In general, (Cys1-Ser68, Val69-Met66, Gly71-Met66, Cys70-Glu67, and Cys70-Thr98) are intimately involved in the conformational stability of TIMP binding interface when bound to MMP. (darkmagenta) also forms complex with (2j0t, colored orange), producing as well as . This network of hydrogen bonds stabilizes the CD and EF loops that compose the binding interface. Importantly, the . However, this MT1-MMP-WT-TIMP-1 complex is not tight-binding. MT1-MMP is unique since even though it exhibits high structural homology to all MMPs, it is not inhibited by TIMP-1, (1bqq). (mutant TIMP-1 is colored in yellow with T98L shown in red) transformed TIMP-1 into a high affinity inhibitor of MT1-MMP (3ma2). WT-TIMP-1, WT-TIMP-2, and TIMP-1 T98L mutant have kinetic dissociation binding constant (KD) 1.53 x 10-6, 5.61 x 10-8, and 8.70 x 10-8, respectively. So, KD of WT-TIMP-2 is 2 orders of magnitude smaller than that of WT-TIMP-1, indicating the weak affinity between MT1-MMP and WT-TIMP-1. The TIMP-1 T98L mutant regained high-affinity binding to MT1-MMP, resulting in a 2 order of magnitude decrease in KD, similar to the case for WT-TIMP-2, the in vivo inhibitor of MT1-MMP. The overall structures of the complexes of MT1-MMP-WT-TIMP-1 and MT1-MMP-mutant-T98L-TIMP-1 are . Even the structure of MT3-MMP-WT-TIMP-1 is (with wild-type and TIMP-1 T98L mutant). , which is situated near the MT1-MMP . So, this T98L replacement may stabilize the entire area by establishing a strong hydrophobic core upon binding to the enzyme. However, it seems unlikely that these additional bonds could account for the entire binding effect between MT1-MMP and TIMP-1. Statistical analysis of the stabilities in the TIMP-1 T98L mutant reveals that the hydrogen bonds network in mutant form is significantly more stable than that in WT-TIMP-1. Mutations that enhance hydrogen bond stability contribute to the stability of the bound-like, less flexible, conformation of TIMP-1, which eventually results in increasing binding affinity for MT1-MMP. Thus, mutation affected the instrinsic dynamics of the inhibitor rather than its structure, thereby facilitating the interaction [5]. |
|
3D structures of matrix metalloproteinase3D structures of matrix metalloproteinase
Updated on 05-August-2018
ReferencesReferences
- ↑ Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999 Jul 30;274(31):21491-4. PMID:10419448
- ↑ Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011 Jan;278(1):16-27. doi: 10.1111/j.1742-4658.2010.07919.x. Epub 2010, Nov 19. PMID:21087457 doi:http://dx.doi.org/10.1111/j.1742-4658.2010.07919.x
- ↑ Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009 May;21(5):1323-33. PMID:19360311
- ↑ Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol. 1993 May;64(5 Suppl):474-84. PMID:8315570 doi:http://dx.doi.org/10.1902/jop.1993.64.5s.474
- ↑ Grossman M, Tworowski D, Dym O, Lee MH, Levy Y, Murphy G, Sagi I. Intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and effects its function. Biochemistry. 2010 Jun 14. PMID:20545310 doi:10.1021/bi902141x